Paris: Sanofi has successfully priced its offering of euro 1.5 billion of notes across 2 tranches:€750 million fixed-rate ...

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million fixed-rate notes, due June 2029, bearing interest at an ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

In an effort to greater prepare HCPs and to avoid potential shortages, the company targets Q3 as the shipment date.

Diabetes continues to emerge as a critical public health challenge globally and in Thailand, with alarming increases among children and youth. This includes both Type 1 diabetes, which requires ...

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

Global Employee Stock Purchase Plan  Paris, June 5, 2025. Sanofi’s global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th ...

The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...

French pharmaceutical giant Sanofi announced on Tuesday that Tzield, the world's first and only therapy approved by the ...

The Ministry of Health is partnering with Sanofi to boost immunisation drives and public awareness from 2025-2027.